tiprankstipranks
Vigil Neuroscience reports Q3 EPS (47c), consensus (54c)
The Fly

Vigil Neuroscience reports Q3 EPS (47c), consensus (54c)

“Our accomplishments in the third quarter have provided significant momentum as we continue to progress our two differentiated TREM2 agonists through clinical development with the goal of reaching patients as quickly as possible,” said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. “We believe our strategic positioning of iluzanebart in ALSP and VG-3927 in Alzheimer’s disease creates two distinct opportunities to establish TREM2 as a therapeutic target and novel pathway for treating neurodegenerative diseases. Our focus remains on execution as we advance closer to important data milestones for our programs in 2025.”

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App